Hydreight Announces Nationwide Expansion of Doctor Network to Meet Demand Across All 50 US States
VANCOUVER, British Columbia and LAS VEGAS, Aug. 24, 2023 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS)(OTCQB: HYDTF)( FSE: SO6), a fast-growing telehealth platform enabling flexible home healthcare, is pleased to announce the ongoing expansion of its doctor network. The Company has successfully increased its network to over 100 physicians spanning across all 50 US states by contracting with an independent network of affiliated medical practices to facilitate the delivery of services to patients. These physician partnerships support screening calls and an increase in consultation requests, as well as new services and offerings that are on the Hydreight platform, where compliance and patient-centred care is of utmost importance.
“Hydreight has become a leader in mobile medical health, providing an unparalleled ecosystem that the Company consistently refines and expands upon to keep up with patient needs and service preferences,” said Shane Madden, CEO of Hydreight. “The expansion of our doctor network complements our established network of nurses, business partners and pharmacies. Delivering exceptional patient care is top priority and with over 100 physicians across all 50 US states, we are on our way to achieve our goal of being the nationwide network of mobile medical clinics.”
Key Highlights:
- Doctor network now includes over 100 physicians across all 50 US states
- Provides increased medical oversight leading to the highest levels of compliance and customer care
- Supports the platforms overall expansion and increase in booking requests, approximately up 195% since January 2023 in compared to the first 6 months of 2022
- Enables Hydreight to onboard more white-label clients
- Hydreight’s doctor network will continue to expand as the Company achieves its growth initiatives
- Extending the telemedicine hours of operation
Expanded Doctor Network
With a commitment to both compliance and creating a seamless and supportive patient/provider experience, the Company will continue to expand its doctor network. The Company has seen approximately a 195% increase in booking requests since January 2023 in comparison to the first 6 months of 2022, commensurate with its expansion and new service offerings. Additionally, through the Company’s white-label strategy, the doctor network extends its reach to benefit other franchises and organizations seeking these services.
Hydreight’s platform continues to expand towards individualized healthcare offerings and patient specific medications and services such as NAD (Nicotinamide Adenine Dinucleotide) and Semaglutide (among others), which are experiencing heightened demand among the broader public. The Hydreight platform connects patients and providers, seamlessly integrates compliance and medical oversight with the convenience and personalized care and one-on-one interactions.
Nicotinamide Adenine Dinucleotide (“NAD”) is a key coenzyme for energy metabolism with diverse benefits, including cognitive enhancement, improved athletic performance, weight management, pain reduction, anti-aging effects, and more.
Semaglutide, a GLP-1 receptor agonist, aids weight loss and diabetes management by lowering blood glucose, slowing gastric emptying, curbing appetite, and has potential applications in heart health, PCOS, addiction, neurodegenerative diseases, and sleep apnea.
About Hydreight Technologies Inc.
Hydreight Technologies Inc. (TSXV: NURS)( OTCQB: HYDTF)( FSE: SO6) is a home healthcare and wellness platform that bridges the gap between providers and patients and empowers nurses, med spa technicians, and other licensed healthcare professionals to deliver services on a flexible schedule or to add mobile services to existing location-based operations. Hydreight facilitates medical director oversight, liability insurance, competitively priced prescriptions via a 503B licensed pharmacy, and more. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, managing patient data, and more, making it possible to deliver mobile medicine across 50 states. Learn more at Hydreight.com.
You can download the Hydreight Wellness App from the Apple App store or Google Play Store , and prospective service providers can sign up at: Hydreight.com/start-a-business/.
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
www.hydreight.com
Telephone: (480) 790 6886
For further information about Hydreight, please contact:
Investor Relations
Contact – Alyssa Barry
Email: ir@hydreight.com
Telephone: 1-833-947-5227
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “approximately” or similar expressions and includes information regarding expectations for the Company’s growth in 2023.
Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or predictions concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
